Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498368 · ClinicalTrials.gov registry record · Phase 4
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT00498368: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00498368 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498368, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.
Interventions
- DRUG Intravenous Rituximab
- DRUG ACE/ARB
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid Fish Oil Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498368
The ClinicalTrials.gov registry entry for NCT00498368 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Intravenous Rituximab is the first listed.
NCT00498368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498368 about?
NCT00498368 is a clinical study titled "Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy". This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intra...
What is the current status of trial NCT00498368?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2009-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00498368?
The interventions under investigation include: Intravenous Rituximab (DRUG), ACE/ARB (DRUG), Omega-3 Fatty Acid Fish Oil Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00498368?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.